New Enterprise Associates is a prominent venture capital firm focusing on investments in technology and healthcare startups. They help entrepreneurs build transformational businesses across multiple stages, sectors, and geographies. With over $19 billion in cumulative committed capital since the firm’s founding in 1977, NEA invests in technology and healthcare companies at all stages in a company’s lifecycle, from the seed stage through the IPO. The firm's long track record of successful investing includes more than 210 portfolio company IPOs and more than 360 acquisitions.

New Enterprise Associates

InterWest invests an average of about $7 - 15 million over the span of their involvement with each company in their portfolio. They invest in companies through the full range of venture investment stages, and investments may be staged over several rounds of financing. Although they generally begin their involvement in the early stages of a company's development, they pursue attractive opportunities based on their individual merits rather than their investment stage.

InterWest Partners

Technology Partners is a venture capital firm specialized in seed-, early-, and later-stage venture and private equity investments.

Technology Partners

Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA.  Domainâ€™s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices, while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics.  The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 200 life-sciences companies.  The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.

Domain Associates

Identifies and invests in new medical technologies and the entrepreneurs developing them to create the next generation of medical practice.

MedVenture Associates

Johnson & Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson & Johnson. JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms, JJDC determines the success of an investment’s performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson & Johnson.  JJDC plays an integral role in the identification of new business opportunities outside of Johnson & Johnson’s traditional portfolio and market presence. JJDC identifies new market opportunities and develops new businesses in emergent health care sectors while also creating support venture investments in alignment with the strategic objectives of Johnson & Johnson operating companies.

Johnson & Johnson Development Corporation

Camden Partners provides growth capital to lower-middle market companies in the education, healthcare and technology-enabled business services sectors. In areas where there is little common knowledge, they make it their business to know intimately the companies and the money managers in which they invest. While many other investment management firms seek to excel as stock-pickers, they pursue opportunities where their experience and influence will make a positive difference to both their investors and the companies in which they invest.

Camden Partners

The Abell Foundation was inaugurated over a half a century ago, Chairman Harry C. Black and the founding board members set an agenda that allocated grants for schools, hospitals, and human service organizations reaching out to the disadvantaged in the Baltimore community and the region. In the past three decades, the Foundation has sharpened its focus to address complex challenges to break through the cycles of urban poverty. Today, the Foundation places the highest priority on creating solutions that are both innovative and will ensure accountability. This is the commitment of The Abell Foundation: to give hope by opening the doors of opportunity to the disenfranchised, knowing that no community can succeed and thrive if those who live on the margins are not included. We invite you to use this website to visit our Publications/Research section where you'll find thought-provoking perspectives on issues affecting the community at large.   The Abell Foundation places a priority on supporting efforts that enhance the quality of life in the areas of community development, education, health and human services, criminal justice and addictions, workforce development and to a lesser extent, conservation/environment, and arts and culture. The Foundation is among the largest private foundations in Maryland with assets of more than $314 million.

Abell Foundation

eNeura Therapeutics

ENeura Therapeutics is a medical technology company developing transcranial magnetic stimulation devices for the treatment of migraines. It pioneers the use of portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for the treatment of migraine. Prescribed by physicians but designed for patient use, it is the first truly portable, convenient TMS product that will allow migraine patients to administer treatment as needed—at home, in the office, or on the go.

eNeura is a pioneering company dedicated to providing innovative therapeutic solutions for individuals suffering from chronic migraine headaches. Their flagship product, SAVI Dual, is a handheld device that utilizes non-invasive single-pulse Transcranial Magnetic Stimulation (sTMS) technology to effectively treat and prevent migraine attacks. This portable and user-friendly device generates a magnetic pulse that modulates electrical signaling in the brain, offering a safe and drug-free alternative to traditional migraine treatments.

eNeura Achieves Record-Breaking Sales and Announces Notice of Allowance for a New Patent on Prophylactic Treatment of Migraine Headache

F3 Wireless

Devices

Eneura

Transforming neurological care with innovation

Neurostimulation Tech

eNeura

eNeura is a pioneering company dedicated to providing innovative therapeutic solutions for individuals suffering from chronic migraine headaches. Their flagship product, SAVI Dual, is a handheld device that utilizes non-invasive single-pulse Transcranial Magnetic Stimulation (sTMS) technology to effectively treat and prevent migraine attacks. This portable and user-friendly device generates a magnetic pulse that modulates electrical signaling in the brain, offering a safe and drug-free alternative to traditional migraine treatments.
In April 2024, eNeura achieved record-breaking sales, experiencing its highest monthly revenue to date. This remarkable surge in demand not only underscores the efficacy of SAVI Dual but also accelerates eNeura's pathway to profitability, enabling faster scaling of their manufacturing capabilities to meet the overwhelming demand.
Furthermore, eNeura announced a Notice of Allowance for a new patent on Prophylactic Treatment of Migraine Headache in April 2024. This patent extends the intellectual property protection for SAVI Dual for an additional 17 years, solidifying eNeura's position as a leader in the migraine treatment landscape.
Notably, eNeura has integrated a wireless Digital Therapeutic platform into the SAVI product, facilitated by F3 Wireless. This platform allows real-world data sharing among patients, physicians, and insurance companies, enabling accurate monitoring of therapeutic benefits and treatment compliance.

Aleva Neurotherapeutics is a medical device company specializing in deep brain stimulation (DBS) systems for treating neurological disorders such as Parkinson's disease and essential tremor. Based in Lausanne, Switzerland, the company was founded as a spin-off from the Swiss Federal Institute of Technology. Aleva pioneered the development of directional DBS leads with its flagship product, the directSTIM DBS system. This technology aims to deliver more precise electrical stimulation to targeted areas of the brain, potentially improving therapeutic benefits and reducing side effects compared to traditional omnidirectional DBS leads.
The directSTIM system features a novel 12-electrode lead design based on microelectromechanical systems (MEMS) technology. This allows for smoother electrode surfaces and customized shapes optimized for implantation in the brain. The system also incorporates 24 independent current sources, enabling greater flexibility in programming and personalizing stimulation patterns to each patient's unique needs. In May 2024, Aleva received CE marking for the directSTIM system, allowing its commercial launch in Europe.
Aleva's expertise in DBS technology is reflected in its robust intellectual property portfolio, comprising 13 patent families and 90 granted patents related to DBS for neurological and psychiatric disorders. The company aims to transform DBS therapy by combining advanced technologies with shared clinical data to improve surgical experiences and patient outcomes.

Aleva Neurotherapeutics

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The company has developed Deep Transcranial Magnetic Stimulation (Deep TMS), a proprietary technology that uses magnetic pulses through a patented H-coil helmet to stimulate deeper and broader brain regions associated with various conditions.
Deep TMS received FDA clearance for treating major depressive disorder (MDD) in 2013, making BrainsWay the first and only TMS company with clinical evidence demonstrating efficacy for this indication. In 2018, the technology obtained FDA clearance for treating obsessive-compulsive disorder (OCD), and in 2021, it was cleared as an aid for short-term smoking cessation.
The Deep TMS treatment is administered through a series of daily sessions over four to six weeks, with each session lasting around 20 minutes. It has been investigated in over 30 randomized clinical trials worldwide, demonstrating its safety and effectiveness. As of April 2021, BrainsWay announced that 100,000 patients have been treated globally with Deep TMS.
In addition to the FDA-cleared indications, BrainsWay is conducting ongoing or planned clinical trials exploring Deep TMS for various psychiatric, neurological, and addiction disorders. The company's commitment to clinical research and building upon its substantial body of evidence positions it as a leader in advancing neuroscience through non-invasive solutions.

Brainsway

Cala Health is a bioelectronic medicine company that has developed the Cala kIQ system, a wearable neuromodulation device that delivers transcutaneous afferent patterned stimulation (TAPS) therapy for the relief of hand tremors in adults with essential tremor and Parkinson's disease. The Cala kIQ system comprises a stimulator, a band with integrated electrodes, and a base station. It utilizes a calibrated TAPS output pattern adjusted to match the patient's unique tremor frequency, providing personalized stimulation to the median and radial nerves of the wrist.
The Cala kIQ system received 510k clearance from the US Food and Drug Administration (FDA) in November 2022 and was launched for human use in June 2023. The device offers treatment sessions of 40 minutes, with a wristband life of 90 days and a shelf life of three months. Patients can review their therapy session results through the MyCala.com patient portal and share them with healthcare providers.
Cala Health has reported positive clinical data demonstrating the effectiveness of TAPS therapy in reducing tremors and improving activities of daily living for essential tremor patients. The company has secured reimbursement and coding from various commercial and government payors, including Medicare, to improve patient access to the therapy.

Cala Health

Cardionomic is a medical device company based in Minneapolis that has developed the Cardiac Pulmonary Nerve Stimulation (CPNS) System, an investigational device designed to treat patients suffering from acute decompensated heart failure (ADHF). The CPNS System consists of a stimulation console and an endovascular catheter that delivers targeted stimulation to the cardiac plexus located in the right pulmonary artery.
The company's approach is founded on the principle that stimulating the autonomic nerves improves a patient's clinical condition by triggering a rebalancing of the autonomic system, shifting it from an imbalanced state into a cycle that enhances the patient's condition even after the therapy is completed. The CPNS System has demonstrated the ability to increase cardiac contractility without significantly affecting heart rate in heart failure patients with reduced ejection fraction.
In January 2024, Cardionomic announced the completion of enrollment in the STIM-ADHF and STOP-ADHF pilot studies, which evaluated the safety and performance of the CPNS System in treating ADHF patients. A total of 35 patients were treated across seven countries. Preliminary results suggest that the CPNS therapy may address the unmet need for more effective treatment options for hospitalized heart failure patients. The pooled data from these studies is planned for publication in early 2024.
The CPNS System leverages engineered electrode surfaces from Pulse Technologies, Inc. to deliver durable electrochemical performance for the neural and cardiac interfacing applications.

Cardionomic

Charco Neurotech was founded in 2019 by Lucy Jung, an industrial designer who was inspired to develop assistive devices for Parkinson's after her own experience as a patient. The CUE1 is a small plastic disc with an electric motor that vibrates at a high frequency in a specialized pattern. This pattern, proven through research, can disrupt the overactive brainwaves that cause Parkinson's symptoms, allowing for improved movement.
The CUE1 attaches to the user's sternum using medical adhesive and is relatively inexpensive compared to other treatments like deep brain stimulation implants. Over 2,000 people in the UK are currently using the CUE1, with a waiting list of almost 20,000 across 120 countries as of March 2024. Charco has raised over USD 10 million in funding and grants, employing around 38 people across the UK, South Korea, and the US.
The device is accompanied by a smartphone app that enables users to personalize the stimulation settings and track their symptoms. Charco aims to obtain regulatory approvals for the CUE1 to be prescribed through healthcare systems like the NHS. In April 2023, Addenbrooke's Hospital in Cambridge became the first hospital to trial the device on inpatients with Parkinson's.
Key customers and partnerships
As of August 2023, over 1,700 people are benefiting from the CUE1 in the UK, and there is a waiting list of over 17,000 people worldwide. Charco has partnered with Dr. Alistair Mackett, a consultant geriatrician at Cambridge University Hospitals, to conduct trials and research on the device's effectiveness.

Charco Neurotech

Companies that offer solutions for pain management, neuropathies, and related disorders and migraines.

Companies that provide solutions for Parkinson's disease, epilepsy, and speech and movement disorders.

Companies that offer treatments for depression, Alzheimer's, and other mental health-related disorders.

Companies that offer solutions for heart-related medical issues such as acute decompensated heart failure and high blood pressure.

Companies that offer solutions for urinary or fecal incontinence, autoimmune diseases and other functional impairments

Companies that offer solutions for hearing or vision impairment, sleep-related conditions, and other disorders, including obesity treatments.

eNeura

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless